Tempest to Present at Upcoming Investor Conferences
H.C. Wainwright23rd Annual Global Investment Conferenceavailable on-demand Monday, September 13, 2021at 7:00 a.m. ET
- Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on
Wednesday September 22, 2021at 9:55 a.m. ET
To access the live or archived recording of the company presentations, please visit the investor section of the Tempest website at https://ir.tempesttx.com.
About Tempest Therapeutics
Tempest Therapeutics is a clinical-stage oncology company advancing small molecules that combine both targeted and immune-mediated mechanisms with the potential to treat a wide range of tumors. The company’s two novel clinical programs are TPST-1495 and TPST-1120, antagonists of EP2/EP4 and PPARα, respectively. Both TPST-1495 and TPST-1120 are advancing through Phase 1 studies designed to study both agents as monotherapies and in combination with other approved agents. Tempest is also developing an orally-available inhibitor of TREX-1 designed to activate selectively the cGAS/